K-BD Group, held the 2nd Pharma & Bio Business Development Strategy Fo…
페이지 정보
본문
K-BD Group, held the 2nd Pharma & Bio Business Development Strategy Forum
21-11-03
Topic of 'Strategies for Coexistence and Cooperation with Bio Startups to Strengthen Global Innovation Competitiveness in the Bio-Health Industry'
The Korea Drug Development Research Association (Chairman Kim Dong-yeon, hereinafter referred to as the New Drug Association) is a pharmaceutical and bio business development research group (Research Chairman Lee Jae-hyun, hereinafter K-BD Group), a group of domestic industry, academia, research, venture and startup business development experts. It was announced that the '2021 2nd Pharmaceutical and Bio Business Development Strategy Forum' was successfully held at COEX, Seoul on November 3 (Wednesday).
The business development strategy forum, co-hosted by the New Drug Association and the Hongneung Jiangsu Special Zone Project Group, was held under the theme of "Strategies for Win-Win Cooperation with Bio Startups to Strengthen Global Innovation Competitiveness in the Bio Health Industry."
In particular, it is their position that by preparing a venue for sharing information on the overall necessary for strategic open innovation with bio-startups, they identified global trends and presented essential action plans in the entire process from the establishment of bio-startups to the execution of exit strategies.
About 170 people from industry, academia, research, government, and universities in the domestic bio-health industry attended and received a great response.
The forum began with a greeting from Jaehyun Lee, Research Chairman of K-BD Group, ▲Identification of global technology trends of major pharmaceutical and bio products using bioinformatics (Consultant Hyojin Park, Clarivate) ▲Startup process and successful exit strategy (Co., Ltd.) Shim Kyung-sik, CEO of SYP) ▲Strategic partnership strategy with pharmaceutical and biotech start-ups (Ildong Pharmaceutical Co., Ltd. Seo Jin-sik) ▲Bio-startup growth strategy (CEO Shin Chan-young, Neuroventi Co., Ltd.) were announced.
▲ Domestic venture capital investment strategies for bio-startups (Daily Partners Co., Ltd. Park In-ae) ▲ Bio-startup technology evaluation (Korea Invention Promotion Association, Manager Koh Ki-young) ▲ Domestic and foreign bio-startup incubation status and prospects (Director Choi Chi-ho, Korea Institute of Science and Technology) ▲ A total of eight topics were presented by experts in each field, such as start-up entrepreneurship and support system (Expert Committee member Lee Kyung, Institute of Startup & Entrepreneurship Promotion).
In addition, on November 4, the New Drug Association and the Hongneung Jiangsu Special Zone Project Group jointly held the 'K-BD Group 2021 2nd Promising Bio Venture Startup Investment Forum' at the same place to promote biotechnology that possesses promising technologies. IR presentations will be held with 15 startup companies participating.
Subsequently, 10 companies announced IRs through the '2021 R&D-centered Excellent Pharmaceutical and Bio Company IR (IPIR 2012)' held by the K-BD Group, discovering promising ventures and start-ups and investing and cooperation between investment institutions and pharmaceutical and bio companies We plan to provide a venue for seeking activation of links, etc.
Meanwhile, the New Drug Association also sponsored and held the 'KOREA LIFE SCIENCE WEEK 2021', a premium exhibition and conference event in the domestic life science field, and in connection with this, pharmaceutical and bio companies, bio ventures and start-ups owned The 'KDRA Bio Innovation Company Joint Public Relations Center' and the 'KDRA Bio Health Partnering & Poster Zone' are operated to actively publicize the excellent technologies available to domestic and foreign companies and investment institutions.
'KDRA Bio Innovation Company Joint Public Relations Center' and 'KDRA Bio Health Partnering & Poster Zone' are held at COEX 1st floor B Hall, Seoul until November 4th. Logics Co., Ltd., Trial Informatics Co., Ltd., Invivotech Co., Ltd., Well Marker Bio Co., Ltd., Helixmith Co., Ltd., Medicine Park Co., Ltd., Seongi Bio Co., Ltd., Time Bio Co., Ltd., Owl Bio Co., Ltd., Inno Pharma Screen Co., Ltd., Hongreung Jiangsu Special Zone Project Group, Korea Nuclear Power Pharmaceutical and bio companies such as medical institutes, bio ventures, start-up companies, and research institutes participate.